Intravitreal injection analysis at the Bascom palmer eye institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis

Ludimila L. Cavalcante, Milena L. Cavalcante, Timothy G. Murray, Michael M. Vigoda, Yolanda Piña, Christina L. Decatur, R. Prince Davis, Lisa C. Olmos, Amy C. Schefler, Michael B. Parrott, Kyle J. Alliman, Harry W Flynn, Andrew A. Moshfeghi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: To report the incidence of endophthalmitis, in addition to its clinical and microbiological aspects, after intravitreal injection of vascular-targeting agents. Methods: A retrospective review of a consecutive series of 10,142 intravitreal injectionsof vasculartargeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, andpreservative-free triamcinolone acetonide) between June 1, 2007 and January 31, 2010,performedby a single service (TGM) at the Bascom Palmer Eye Institute. Results: One case of clinically-suspected endophthalmitis was identified out of a total of 10,142injections (0.009%), presenting within three days of injection of bevacizumab. The case wasculture-positive for Staphylococcus epidermidis. Final visual acuity was 20/40 after pars planavitrectomy surgery. Conclusions: In this series, the incidence of culture-positive endophthalmitis after intravitrealinjection of vascular agents in an outpatient setting was very low. We believe that following astandardized injection protocol, adherence to sterile techniques and proper patient follow-upare determining factors for low incidence rates.

Original languageEnglish
Pages (from-to)519-524
Number of pages6
JournalClinical Ophthalmology
Volume4
Issue number1
StatePublished - Sep 3 2010

Fingerprint

Intravitreal Injections
Endophthalmitis
Triamcinolone Acetonide
Blood Vessels
Incidence
Injections
Staphylococcus epidermidis
Visual Acuity
Outpatients
Therapeutics
Bevacizumab

Keywords

  • Endophthalmitis
  • Intravitreal injections
  • Vascular targeting agent

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Cavalcante, L. L., Cavalcante, M. L., Murray, T. G., Vigoda, M. M., Piña, Y., Decatur, C. L., ... Moshfeghi, A. A. (2010). Intravitreal injection analysis at the Bascom palmer eye institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clinical Ophthalmology, 4(1), 519-524.

Intravitreal injection analysis at the Bascom palmer eye institute : Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. / Cavalcante, Ludimila L.; Cavalcante, Milena L.; Murray, Timothy G.; Vigoda, Michael M.; Piña, Yolanda; Decatur, Christina L.; Davis, R. Prince; Olmos, Lisa C.; Schefler, Amy C.; Parrott, Michael B.; Alliman, Kyle J.; Flynn, Harry W; Moshfeghi, Andrew A.

In: Clinical Ophthalmology, Vol. 4, No. 1, 03.09.2010, p. 519-524.

Research output: Contribution to journalArticle

Cavalcante, LL, Cavalcante, ML, Murray, TG, Vigoda, MM, Piña, Y, Decatur, CL, Davis, RP, Olmos, LC, Schefler, AC, Parrott, MB, Alliman, KJ, Flynn, HW & Moshfeghi, AA 2010, 'Intravitreal injection analysis at the Bascom palmer eye institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis', Clinical Ophthalmology, vol. 4, no. 1, pp. 519-524.
Cavalcante, Ludimila L. ; Cavalcante, Milena L. ; Murray, Timothy G. ; Vigoda, Michael M. ; Piña, Yolanda ; Decatur, Christina L. ; Davis, R. Prince ; Olmos, Lisa C. ; Schefler, Amy C. ; Parrott, Michael B. ; Alliman, Kyle J. ; Flynn, Harry W ; Moshfeghi, Andrew A. / Intravitreal injection analysis at the Bascom palmer eye institute : Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. In: Clinical Ophthalmology. 2010 ; Vol. 4, No. 1. pp. 519-524.
@article{1210bef0dc5a4f65b8ec1929552cca2b,
title = "Intravitreal injection analysis at the Bascom palmer eye institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis",
abstract = "Objective: To report the incidence of endophthalmitis, in addition to its clinical and microbiological aspects, after intravitreal injection of vascular-targeting agents. Methods: A retrospective review of a consecutive series of 10,142 intravitreal injectionsof vasculartargeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, andpreservative-free triamcinolone acetonide) between June 1, 2007 and January 31, 2010,performedby a single service (TGM) at the Bascom Palmer Eye Institute. Results: One case of clinically-suspected endophthalmitis was identified out of a total of 10,142injections (0.009{\%}), presenting within three days of injection of bevacizumab. The case wasculture-positive for Staphylococcus epidermidis. Final visual acuity was 20/40 after pars planavitrectomy surgery. Conclusions: In this series, the incidence of culture-positive endophthalmitis after intravitrealinjection of vascular agents in an outpatient setting was very low. We believe that following astandardized injection protocol, adherence to sterile techniques and proper patient follow-upare determining factors for low incidence rates.",
keywords = "Endophthalmitis, Intravitreal injections, Vascular targeting agent",
author = "Cavalcante, {Ludimila L.} and Cavalcante, {Milena L.} and Murray, {Timothy G.} and Vigoda, {Michael M.} and Yolanda Pi{\~n}a and Decatur, {Christina L.} and Davis, {R. Prince} and Olmos, {Lisa C.} and Schefler, {Amy C.} and Parrott, {Michael B.} and Alliman, {Kyle J.} and Flynn, {Harry W} and Moshfeghi, {Andrew A.}",
year = "2010",
month = "9",
day = "3",
language = "English",
volume = "4",
pages = "519--524",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Intravitreal injection analysis at the Bascom palmer eye institute

T2 - Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis

AU - Cavalcante, Ludimila L.

AU - Cavalcante, Milena L.

AU - Murray, Timothy G.

AU - Vigoda, Michael M.

AU - Piña, Yolanda

AU - Decatur, Christina L.

AU - Davis, R. Prince

AU - Olmos, Lisa C.

AU - Schefler, Amy C.

AU - Parrott, Michael B.

AU - Alliman, Kyle J.

AU - Flynn, Harry W

AU - Moshfeghi, Andrew A.

PY - 2010/9/3

Y1 - 2010/9/3

N2 - Objective: To report the incidence of endophthalmitis, in addition to its clinical and microbiological aspects, after intravitreal injection of vascular-targeting agents. Methods: A retrospective review of a consecutive series of 10,142 intravitreal injectionsof vasculartargeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, andpreservative-free triamcinolone acetonide) between June 1, 2007 and January 31, 2010,performedby a single service (TGM) at the Bascom Palmer Eye Institute. Results: One case of clinically-suspected endophthalmitis was identified out of a total of 10,142injections (0.009%), presenting within three days of injection of bevacizumab. The case wasculture-positive for Staphylococcus epidermidis. Final visual acuity was 20/40 after pars planavitrectomy surgery. Conclusions: In this series, the incidence of culture-positive endophthalmitis after intravitrealinjection of vascular agents in an outpatient setting was very low. We believe that following astandardized injection protocol, adherence to sterile techniques and proper patient follow-upare determining factors for low incidence rates.

AB - Objective: To report the incidence of endophthalmitis, in addition to its clinical and microbiological aspects, after intravitreal injection of vascular-targeting agents. Methods: A retrospective review of a consecutive series of 10,142 intravitreal injectionsof vasculartargeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, andpreservative-free triamcinolone acetonide) between June 1, 2007 and January 31, 2010,performedby a single service (TGM) at the Bascom Palmer Eye Institute. Results: One case of clinically-suspected endophthalmitis was identified out of a total of 10,142injections (0.009%), presenting within three days of injection of bevacizumab. The case wasculture-positive for Staphylococcus epidermidis. Final visual acuity was 20/40 after pars planavitrectomy surgery. Conclusions: In this series, the incidence of culture-positive endophthalmitis after intravitrealinjection of vascular agents in an outpatient setting was very low. We believe that following astandardized injection protocol, adherence to sterile techniques and proper patient follow-upare determining factors for low incidence rates.

KW - Endophthalmitis

KW - Intravitreal injections

KW - Vascular targeting agent

UR - http://www.scopus.com/inward/record.url?scp=77956100882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956100882&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77956100882

VL - 4

SP - 519

EP - 524

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

IS - 1

ER -